Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Phase 3 Completed 187 enrolled Chugai Pharmaceutical

RandomizedParallel-groupOpen-labelTreatment

Summary

This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of subcutaneous R744 in renal anemia patients on Predialysis.

Timeline

Start: 2007-06
Primary completion: 2008-01
Completion: 2008-11

Publications

Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	epoetin alfa	Protein / enzyme biologic	3000 iu	Subcutaneous
Comparator	epoetin alfa	Protein / enzyme biologic	12000 iu	Subcutaneous
Subject	methoxy polyethylene glycol-epoetin beta	Protein / enzyme biologic	25 ug	Subcutaneous
Subject	methoxy polyethylene glycol-epoetin beta	Protein / enzyme biologic	250 ug	Subcutaneous

Indications

No indication recorded.